Pure Global
NCT05840068

IGF Level in Breast Cancer Patients Treated With Metformin

Metformin Effect as a Chemotherapeutic Adjuvant on Level of IGF in Non-diabetic Breast Cancer Patients
Beni-Suef University·Phase 4·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Breast Cancer Female
Drug/Device/Intervention
MetFORMIN 500 Mg Oral Tablet
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Beni-Suef University
Location
Banī Suwayf, Egypt
Timeline & enrollment
Phase
Phase 4
Start date
Jun 01, 2020
End date
Jul 31, 2021
Enrollment
107 participants
Primary outcome

IGF-1 levels

Summary

The purpose of this study is to examine the impact of metformin as an adjuvant to
 chemotherapy on IGF levels in both progressing and non progressing cases of metastatic breast
 cancer in female patients.

ICD-10 classifications
Malignant neoplasm: Breast, unspecifiedMalignant neoplasm of breastMalignant neoplasm of breastCarcinoma in situ of breast, unspecifiedPersonal history of malignant neoplasm of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05840068
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05840068 through Pure Global AI's free database. This Phase 4 trial is sponsored by Beni-Suef University and is currently Completed. The study focuses on Breast Cancer Female. Target enrollment is 107 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.